Aurobindo Pharma today said it has received tentative approval of the US Food and Drug Administration (FDA) for the generic version of Crestor tablets used in the cardiovascular therapeutic area.
The company has received the approval for Rosuvastatin tablets, which is generic version of US-based pharmaceutical firm IPR Inc, in 5mg, 10mg, 20mg and 40 mg strength, Aurobindo Pharma said in a filing to the Bombay Stock Exchange (BSE).
The company said it has filed the abbreviated new drug application (ANDA) with FDA with Paragraph IV certification with first to file status.
Paragraph IV certification with first to file status, gives generic firm an opportunity to launch the drug in the US with a exclusive marketing rights of up to 180 days.
The company is currently facing litigation related to its drug application in the US District Court of Dilaware alleging patent infringements.
The total market for the drug in the US is around $2.9 billion, according to market research firm Newport, the company said.
With this, the total number of ANDA approvals with Aurobindo has gone up to 116, including 86 final approvals and 30 tentative approvals.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app